Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback